23 results
20-F/A
2022 FY
EX-4.9
IPHA
Innate Pharma
20 Apr 23
Annual report (foreign) (amended)
8:47am
, loss, damage, claim, injury, costs or expenses (collectively, “Damages”) that are caused by (whether directly or indirectly):
11.1.1 any failure
20-F
4wal5f 4j
24 Apr 20
Annual report (foreign)
10:43am
424B4
bc7 1mhjdn0yca
18 Oct 19
Prospectus supplement with pricing info
4:08pm
F-1/A
qz3nh97wj
4 Oct 19
Registration statement (foreign) (amended)
4:56pm
F-1
EX-10.2
pdz3v38h 4g0
20 Sep 19
Registration statement (foreign)
4:08pm
F-1
8t49l3zsevd
20 Sep 19
Registration statement (foreign)
4:08pm
F-1
EX-10.1
szwdzcl
20 Sep 19
Registration statement (foreign)
4:08pm
F-1
EX-10.5
0yion1hn d0shx8zfcp
20 Sep 19
Registration statement (foreign)
4:08pm
F-1
EX-10.3
n3h33ohzgm
20 Sep 19
Registration statement (foreign)
4:08pm
F-1
EX-10.4
9arj5
20 Sep 19
Registration statement (foreign)
4:08pm
DRS/A
EX-10.3
3c0 5t1mdtvba8ss
30 Aug 19
Draft registration statement (amended)
12:00am
DRS/A
j14y wj2wmjl
30 Aug 19
Draft registration statement (amended)
12:00am
DRS/A
EX-10.4
t87re57w4qg7qmayi
30 Aug 19
Draft registration statement (amended)
12:00am
DRS/A
EX-10.1
0ijdipe82ek
30 Aug 19
Draft registration statement (amended)
12:00am
DRS/A
EX-10.2
qzvl56j9ez9
30 Aug 19
Draft registration statement (amended)
12:00am